Chronic therapy is essential for PCV patients, even after resolution of pigment epithelial detachment, to prevent recurrence. Faricimab and aflibercept show efficacy in DME, RVO, and nAMD, but not all ...
Global healthcare company Grifols has partnered with BARDA, the Biomedical Advanced Research and Development Authority, to ...
New data support a change in management of the common eye disease glaucoma from eye drops, the current standard of care, to a ...